Signaturefd LLC Has $452,000 Stake in Illumina, Inc. $ILMN

Key Points

• Signaturefd LLC increased its stake in Illumina, Inc. by 194.9%, owning 4,742 shares valued at $452,000 as of the latest filing.
• Overall, 89.42% of Illumina's stock is owned by institutional investors, with multiple firms increasing their holdings significantly in the past quarters.
• Illumina's recent earnings report showed $1.19 EPS, surpassing estimates, but revenue was down 4.8% year-over-year at $1.06 billion.

Signaturefd LLC grew its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 194.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,742 shares of the life sciences company's stock after purchasing an additional 3,134 shares during the quarter. Signaturefd LLC's holdings in Illumina were worth $452,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ILMN. Rise Advisors LLC raised its holdings in shares of Illumina by 173.6% in the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company's stock valued at $28,000 after buying an additional 224 shares during the last quarter. Rakuten Securities Inc. raised its stake in shares of Illumina by 290.3% in the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock worth $29,000 after acquiring an additional 270 shares during the last quarter. Center for Financial Planning Inc. bought a new position in shares of Illumina in the first quarter worth about $33,000. PFS Partners LLC lifted its position in shares of Illumina by 400.0% during the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock worth $40,000 after purchasing an additional 400 shares in the last quarter. Finally, Golden State Wealth Management LLC grew its stake in shares of Illumina by 123.2% during the first quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company's stock valued at $42,000 after purchasing an additional 292 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ILMN. Morgan Stanley boosted their price objective on shares of Illumina from $100.00 to $105.00 and gave the stock an "equal weight" rating in a research report on Monday, August 4th. Daiwa America downgraded Illumina from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 12th. Citigroup lowered Illumina from a "hold" rating to a "strong sell" rating and cut their price target for the company from $85.00 to $80.00 in a research note on Wednesday, July 9th. Daiwa Capital Markets lowered Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price objective for the company. in a research report on Tuesday, August 12th. Finally, Stephens set a $110.00 target price on shares of Illumina and gave the company an "overweight" rating in a research report on Monday, August 4th. Six research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Illumina has an average rating of "Hold" and an average target price of $123.06.

Illumina Trading Up 3.4%

NASDAQ ILMN opened at $94.97 on Wednesday. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66. The stock has a 50-day simple moving average of $99.42 and a 200 day simple moving average of $89.55. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $14.60 billion, a PE ratio of 12.02, a P/E/G ratio of 2.22 and a beta of 1.43.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. The firm had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company's revenue was down 4.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.